The stability of epigenetic factor ASXL1 is regulated through ubiquitination and USP7-mediated deubiquitination

Leukemia

Volumn 29, Issue 11, 2015, Pages 2257-2260

  Inoue, D ^a   Nishimura, K ^a   Kozuka Hata, H ^a   Oyama, M ^a   Kitamura, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADDITIONAL SEX COMBS LIKE TRANSCRIPTIONAL REGULATOR 1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DEUBIQUITINASE; TRANSCRIPTION FACTOR; UBIQUITIN SPECIFIC PEPTIDASE 7; UNCLASSIFIED DRUG; ASXL1 PROTEIN, HUMAN; PROTEIN P53; REPRESSOR PROTEIN; TP53 PROTEIN, HUMAN; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN;

EPIGENETIC REPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; HEK293 CELL LINE; HL 60 CELL LINE; HUMAN; LETTER; MASS SPECTROMETRY; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN STABILITY; UBIQUITINATION; PHYSIOLOGY;

HEK293 CELLS; HL-60 CELLS; HUMANS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE; UBIQUITINATION;

EID: 84946496516     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.90     Document Type: Letter

References (15)

1. Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013; 210: 2641-2659.
2. Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S et al. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood 2014; 123: 541-553.
3. Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T et al. Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. J Clin Invest 2013; 123: 4627-4640.
4. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-2506.
5. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 2011; 44: 325-340.
6. Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C et al. Loss-offunction Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010; 115: 38-46.
7. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247.
8. Sanchez-Pulido L, Kong L, Ponting CP. A common ancestry for BAP1 and Uch37 regulators. Bioinformatics 2012; 28: 1953-1956.
9. Chen TC, Hou HA, Chou WC, Tang JL, Kuo YY, Chen CY et al. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J 2014; 4: e177.
10. Eletr ZM, Wilkinson KD. Regulation of proteolysis by human deubiquitinating enzymes. Biochim Biophys Acta 2014; 1843: 114-128.
11. Maertens GN, El Messaoudi-Aubert S, Elderkin S, Hiom K, Peters G. Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of the INK4a tumour suppressor. EMBO J 2010; 29: 2553-2565.
12. Cole AJ, Clifton-Bligh RJ, Marsh DJ. Ubiquitination and cancer: Histone H2B monoubiquitination-roles to play in human malignancy. Endocr Relat Cancer 2015; 22: 19-33.
13. Huether R, Dong L, Chen X, Wu G, Parker M, Wei L et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun 2014; 5: 3630.
14. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004; 13: 879-886.
15. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008; 455: 813-817.